Citizens Jmp Reaffirms “Market Outperform” Rating for Opus Genetics (NASDAQ:IRD)

Posted by Brenda Bartman on Oct 16th, 2026

Opus Genetics (NASDAQ:IRD – Get Free Report)‘s stock had its “market outperform” rating reiterated by research analysts at Citizens Jmp in a research note issued to investors on Friday, Benzinga reports. They presently have a $17.00 price target on the stock. Citizens Jmp’s target price points to a potential upside of 342.71% from the company’s current price.

IRD has been the subject of a number of other reports. Chardan Capital reissued a “buy” rating and issued a $16.00 price target on shares of Opus Genetics in a research note on Friday, October 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Opus Genetics in a report on Thursday. BTIG Research reissued a “buy” rating and issued a $12.00 target price on shares of Opus Genetics in a research report on Wednesday, September 9th. Oppenheimer increased their target price on Opus Genetics from $10.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Opus Genetics in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $12.71.

Get Our Latest Analysis on Opus Genetics

Opus Genetics Price Performance

Opus Genetics stock traded down $0.21 during mid-day trading on Friday, reaching $3.84. 2,525,524 shares of the company traded hands, compared to its average volume of 1,434,540. The firm’s 50 day moving average price is $4.51 and its 200 day moving average price is $4.39. The firm has a market capitalization of $317.38 million, a price-to-earnings ratio of -2.84 and a beta of 0.62. Opus Genetics has a 52-week low of $1.70 and a 52-week high of $7.07.

Opus Genetics (NASDAQ:IRD – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.02. The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $2.63 million. On average, sell-side analysts anticipate that Opus Genetics will post -0.97 EPS for the current year.

Insider Buying and Selling

In other news, CFO Robert E. Gagnon sold 28,000 shares of Opus Genetics stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total transaction of $127,120.00. Following the completion of the transaction, the chief financial officer directly owned 556,375 shares in the company, valued at approximately $2,525,942.50. This trade represents a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 556,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $4.96, for a total value of $2,757,760.00. Following the completion of the sale, the director directly owned 3,236,171 shares in the company, valued at approximately $16,051,408.16. This represents a 14.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 613,331 shares of company stock valued at $2,971,509 over the last quarter. Corporate insiders own 11.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRD. Sanders Morris Harris LLC bought a new stake in Opus Genetics in the third quarter worth $58,000. Opaleye Management Inc. grew its stake in shares of Opus Genetics by 0.4% in the second quarter. Opaleye Management Inc. now owns 1,125,000 shares of the company’s stock worth $4,624,000 after acquiring an additional 5,000 shares during the last quarter. Engineers Gate Manager LP bought a new position in shares of Opus Genetics during the second quarter valued at $50,000. Squarepoint Ops LLC bought a new position in shares of Opus Genetics during the second quarter valued at $1,360,000. Finally, Nantahala Capital Management LLC purchased a new position in shares of Opus Genetics in the 2nd quarter worth about $12,582,185. Institutional investors own 14.97% of the company’s stock.

Opus Genetics Company Profile

(Get Free Report)

Opus Genetics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, a group of rare disorders that can cause progressive vision loss and blindness. The company’s research is centered on therapies intended to address the underlying genetic causes of these conditions rather than treating only their symptoms.

Opus Genetics is advancing an investigational pipeline of adeno-associated virus-based gene therapy candidates for diseases involving mutations in genes important to retinal function.